Matching articles for "lubiprostone"
Vibrant – An Oral Vibrating Capsule for Chronic Idiopathic Constipation
The Medical Letter on Drugs and Therapeutics • May 1, 2023; (Issue 1675)
The Vibrant orally administered vibrating capsule
(Vibrant Gastro), an FDA-cleared medical device, is
now available by prescription for treatment of adults
with chronic idiopathic constipation (CIC) who...
The Vibrant orally administered vibrating capsule
(Vibrant Gastro), an FDA-cleared medical device, is
now available by prescription for treatment of adults
with chronic idiopathic constipation (CIC) who have
not experienced relief of their bowel symptoms
by using laxative therapies at the recommended
dosage for at least one month. It is the first drug-free
treatment to be authorized by the FDA for this
indication.
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • December 12, 2022; (Issue 1665)
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.
Tenapanor (Ibsrela) for Irritable Bowel Syndrome with Constipation
The Medical Letter on Drugs and Therapeutics • June 13, 2022; (Issue 1652)
The FDA has approved tenapanor (Ibsrela - Ardelyx),
a sodium/hydrogen exchanger 3 (NHE3) inhibitor, for
twice-daily oral treatment of irritable bowel syndrome
with constipation (IBS-C) in adults. Tenapanor...
The FDA has approved tenapanor (Ibsrela - Ardelyx),
a sodium/hydrogen exchanger 3 (NHE3) inhibitor, for
twice-daily oral treatment of irritable bowel syndrome
with constipation (IBS-C) in adults. Tenapanor is the
first NHE3 inhibitor to become available in the US.
Drugs for Irritable Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • March 23, 2020; (Issue 1594)
Irritable bowel syndrome (IBS) is a common disorder
characterized by recurrent abdominal pain and altered
bowel habits, often accompanied by bloating.IBS
is classified according to the predominant...
Irritable bowel syndrome (IBS) is a common disorder
characterized by recurrent abdominal pain and altered
bowel habits, often accompanied by bloating.IBS
is classified according to the predominant bowel
symptom as IBS with constipation (IBS-C), IBS with
diarrhea (IBS-D), mixed type (IBS-M), or unclassified
(IBS-U). Alterations in the microbiome, stress
responses, sensory and motor function of the gut,
and host genetic factors may be contributing factors.
Since the exact cause of IBS is unknown, the goal of
treatment is symptom control.
Table: Safety of Drugs for IBS in Pregnancy and Lactation (online only)
The Medical Letter on Drugs and Therapeutics • March 23, 2020; (Issue 1594)
...
View the Table: Safety of Drugs for IBS in Pregnancy and Lactation
Prucalopride (Motegrity) for Chronic Idiopathic Constipation
The Medical Letter on Drugs and Therapeutics • June 3, 2019; (Issue 1573)
The FDA has approved the 5-HT4 receptor agonist
prucalopride (Motegrity – Shire) for treatment of chronic
idiopathic constipation (CIC) in adults. Prucalopride is
the only drug currently approved in the US...
The FDA has approved the 5-HT4 receptor agonist
prucalopride (Motegrity – Shire) for treatment of chronic
idiopathic constipation (CIC) in adults. Prucalopride is
the only drug currently approved in the US for treatment
of CIC that stimulates colonic peristalsis. It has been
available in Europe and Canada for several years.
Expanded Table: Some Drugs for Chronic Idiopathic Constipation (online only)
The Medical Letter on Drugs and Therapeutics • June 3, 2019; (Issue 1573)
...
View the Expanded Table: Some Drugs for Chronic Idiopathic Constipation
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • April 9, 2018; (Issue 1544)
Use of nonopioid drugs for pain was reviewed in a
previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations...
Use of nonopioid drugs for pain was reviewed in a
previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations of full opioid agonists should generally be used for acute pain that is severe enough to require treatment with an opioid. Use of extended-release or long-acting opioid formulations initially and treatment durations >1 week have been associated with an increased risk of unintended long-term use.
Naldemedine (Symproic) for Opioid-Induced Constipation
The Medical Letter on Drugs and Therapeutics • December 4, 2017; (Issue 1535)
The FDA has approved the opioid receptor antagonist
naldemedine (Symproic – Shionogi) for treatment
of opioid-induced constipation (OIC) in adults with
chronic noncancer pain. Naldemedine is the third...
The FDA has approved the opioid receptor antagonist
naldemedine (Symproic – Shionogi) for treatment
of opioid-induced constipation (OIC) in adults with
chronic noncancer pain. Naldemedine is the third oral
peripherally-acting mu-opioid receptor antagonist
(PAMORA) to be approved for this indication; naloxegol
(Movantik) and methylnaltrexone (Relistor) were
approved earlier.
Plecanatide (Trulance) for Chronic Idiopathic Constipation
The Medical Letter on Drugs and Therapeutics • April 24, 2017; (Issue 1519)
The FDA has approved plecanatide (Trulance –
Synergy), a guanylate cyclase-C receptor agonist,
for treatment of chronic idiopathic constipation (CIC)
in adults. Linaclotide (Linzess), another...
The FDA has approved plecanatide (Trulance –
Synergy), a guanylate cyclase-C receptor agonist,
for treatment of chronic idiopathic constipation (CIC)
in adults. Linaclotide (Linzess), another guanylate
cyclase-C receptor agonist, and lubiprostone (Amitiza),
a chloride channel activator, were approved earlier for
treatment of CIC in adults.
Drugs for Irritable Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • September 26, 2016; (Issue 1504)
Irritable bowel syndrome (IBS) is a common disorder
characterized by chronic, intermittent abdominal pain
or discomfort and altered bowel habits. It is subtyped
according to the predominant bowel symptom as...
Irritable bowel syndrome (IBS) is a common disorder
characterized by chronic, intermittent abdominal pain
or discomfort and altered bowel habits. It is subtyped
according to the predominant bowel symptom as IBS
with constipation (IBS-C), IBS with diarrhea (IBS-D),
mixed type (IBS-M), or unclassified (IBS-U). Since the
exact cause of IBS is unknown, the goal of treatment
is symptom control.
Naloxegol (Movantik) for Opioid-Induced Constipation
The Medical Letter on Drugs and Therapeutics • September 28, 2015; (Issue 1478)
The FDA has approved naloxegol (Movantik –
AstraZeneca), a pegylated derivative of the opioid
antagonist naloxone, for oral treatment of opioid-induced
constipation in adults with chronic noncancer
pain....
The FDA has approved naloxegol (Movantik –
AstraZeneca), a pegylated derivative of the opioid
antagonist naloxone, for oral treatment of opioid-induced
constipation in adults with chronic noncancer
pain. It is the only oral opioid antagonist approved for
this indication in the US.
Rifaximin (Xifaxan) for Irritable Bowel Syndrome with Diarrhea
The Medical Letter on Drugs and Therapeutics • August 3, 2015; (Issue 1474)
Rifaximin (Xifaxan – Salix), a minimally absorbed
oral antibiotic approved previously to treat travelers'
diarrhea and to reduce the risk of recurrent hepatic
encephalopathy, has now been approved by the...
Rifaximin (Xifaxan – Salix), a minimally absorbed
oral antibiotic approved previously to treat travelers'
diarrhea and to reduce the risk of recurrent hepatic
encephalopathy, has now been approved by the FDA
for treatment of irritable bowel syndrome with diarrhea
(IBS-D). Eluxadoline (Viberzi – Actavis), a mu-opioid
receptor agonist, was also recently approved for IBS-D
and will be reviewed in a future issue.
Lubiprostone (Amitiza) for Opioid-Induced Constipation
The Medical Letter on Drugs and Therapeutics • June 10, 2013; (Issue 1418)
The FDA has approved use of lubiprostone (Amitiza)
for treatment of opioid-induced constipation in adults
with chronic non-cancer pain. The drug was previously
approved for chronic idiopathic constipation...
The FDA has approved use of lubiprostone (Amitiza)
for treatment of opioid-induced constipation in adults
with chronic non-cancer pain. The drug was previously
approved for chronic idiopathic constipation and irritable
bowel syndrome with constipation.
Linaclotide (Linzess) for Constipation
The Medical Letter on Drugs and Therapeutics • November 12, 2012; (Issue 1403)
Linaclotide (lin´´ a kloe´ tide; Linzess – Ironwood/Forest),
a guanylate cyclase-C receptor agonist, was recently
approved by the FDA for oral treatment of chronic idiopathic
constipation (CIC) and...
Linaclotide (lin´´ a kloe´ tide; Linzess – Ironwood/Forest),
a guanylate cyclase-C receptor agonist, was recently
approved by the FDA for oral treatment of chronic idiopathic
constipation (CIC) and irritable bowel syndrome
with constipation (IBS-C) in adults. It is the second drug
approved for this indication; lubiprostone (Amitiza), a
metabolite of prostaglandin E1, was the first.
Drugs for Irritable Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • July 1, 2011; (Issue 107)
Irritable bowel syndrome (IBS) is a common disorder,
occurring in up to 15% of the US population; it is 2-2.5 times more frequent in women than in men. IBS
is characterized by chronic, intermittent...
Irritable bowel syndrome (IBS) is a common disorder,
occurring in up to 15% of the US population; it is 2-2.5 times more frequent in women than in men. IBS
is characterized by chronic, intermittent abdominal
pain or discomfort accompanied by altered bowel
habits. Since the underlying mechanisms of disease
remain unclear, management of IBS focuses on symptom
control.
Lubiprostone (Amitiza) for Irritable Bowel Syndrome with Constipation
The Medical Letter on Drugs and Therapeutics • July 14, 2008; (Issue 1290)
Lubiprostone (Amitiza), which was previously approved for treatment of chronic idiopathic constipation in adults, has now also been approved in a lower dose for use in women with irritable bowel syndrome with...
Lubiprostone (Amitiza), which was previously approved for treatment of chronic idiopathic constipation in adults, has now also been approved in a lower dose for use in women with irritable bowel syndrome with constipation (IBS-C). Since tegaserod (Zelnorm) has been withdrawn from the market,2 lubiprostone is the only drug approved by the FDA for treatment of this common condition.
Lubiprostone (Amitiza) for Chronic Constipation
The Medical Letter on Drugs and Therapeutics • June 5, 2006; (Issue 1236)
The FDA has approved lubiprostone (Amitiza - Sucampo/Takeda), a chloride channel activator, for treatment of chronic idiopathic constipation in adults. The only other prescription drug approved by the FDA for...
The FDA has approved lubiprostone (Amitiza - Sucampo/Takeda), a chloride channel activator, for treatment of chronic idiopathic constipation in adults. The only other prescription drug approved by the FDA for this indication (in 2004 for adults <= 65 years old) is tegaserod (Zelnorm), a partial agonist of serotonin that is also approved for constipation-predominant irritable bowel syndrome in women. Of course, numerous over-the-counter products are available for treatment of constipation.